Most Read

FDA has provided the breakthrough therapy status based on data from the BPDCN cohort of the first-in-human study of IMGN632, said ImmunoGen. IMGN632 is a CD123-targeting ADC, which

Farxiga is an oral, once-daily sodium-glucose co-transporter-2 inhibitor (SGLT2 inhibitor). Its breakthrough therapy designation in chronic kidney disease was driven by the findings of phase 3 DAPA-CKD trial.

The deal is valued at around $647m on an enterprise basis, including debt obligations expected to be assumed or repaid net of cash. As per terms of the

Under the deal, CStone and Pfizer will involve in the development and commercialisation of CStone’s sugemalimab, an investigational anti-PD-L1 monoclonal antibody, in mainland China. They will also co-develop

The randomised, double-blind, exploratory phase I trial A has been designed to evaluate the pharmacokinetic profile, safety and tolerability of a continuous daily dosing regimen of Ivermectin in

Koligo is involved in the development of personalised cell therapies using the cells of the patient. The company already commercialised its first commercial product Kyslecel for the treatment

Xeljanz, claimed to be the first and only Janus kinase (JAK) inhibitor approved in the US to treat pcJIA, is available in two formulations such as a tablet

The company’s investigational new drug application (IND) for the clinical trial will be on partial clinical hold until the regulator receives satisfying answers for the questions. The partial

Nucala has been approved to treat adult and paediatric patients aged 12 years and older with HES ≥ six months without an identifiable non-haematologic secondary cause. Mepolizumab, the